LLY

1,120.29

-0.83%↓

JNJ

235.16

-0.31%↓

ABBV

222.63

+0.73%↑

UNH

408.01

-0.62%↓

MRK

115.09

+0.17%↑

LLY

1,120.29

-0.83%↓

JNJ

235.16

-0.31%↓

ABBV

222.63

+0.73%↑

UNH

408.01

-0.62%↓

MRK

115.09

+0.17%↑

LLY

1,120.29

-0.83%↓

JNJ

235.16

-0.31%↓

ABBV

222.63

+0.73%↑

UNH

408.01

-0.62%↓

MRK

115.09

+0.17%↑

LLY

1,120.29

-0.83%↓

JNJ

235.16

-0.31%↓

ABBV

222.63

+0.73%↑

UNH

408.01

-0.62%↓

MRK

115.09

+0.17%↑

LLY

1,120.29

-0.83%↓

JNJ

235.16

-0.31%↓

ABBV

222.63

+0.73%↑

UNH

408.01

-0.62%↓

MRK

115.09

+0.17%↑

Search

Sana Biotechnology Inc

Open

SectorHealthcare

2.84

Overview

Share price change

24h

Current

Min

2.79

Max

2.87

Key metrics

By Trading Economics

Income

12M

-47M

EPS

-0.171

Employees

142

EBITDA

23M

-35M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+243.86% upside

Dividends

By Acuity

Next Earnings

7 Aug 2026

Market Stats

By TradingEconomics

Market Cap

-215M

746M

Previous open

2.84

Previous close

2.84

News Sentiment

By Acuity

25%

75%

62 / 342 Healthcare

Sana Biotechnology Inc Chart

Past performance is not a reliable indicator of future results.

About Sana Biotechnology Inc

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.
help-icon Live chat